0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > MMP-9

MMP-9

Brief Information

Name:Matrix metalloproteinase 9
Target Synonym:Type V Collagenase,Gelatinase B,EC 3.4.24.35,MANDP2,Matrix Metalloproteinase 9,CLG4B,MMP9,Matrix Metallopeptidase 9,Matrix Metalloproteinase 9 (Gelatinase B, 92kDa Gelatinase, 92kDa Type IV Collagenase),GELB,Matrix Metalloproteinase-9,92 KDa Type IV Collagenase,Macrophage Gelatinase,92 kDa gelatinase,MMP-9,Matrix Metallopeptidase 9 (Gelatinase B, 92kDa Gelatinase, 92kDa Type IV Collagenase),EC:3.4.24.35,EC 3.4.24
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

MM9-H52H9-MALS-HPLC
MMP-9 MALS images

The purity of Human MMP-9 (20-707), His Tag (Cat. No. MM9-H52H9) is more than 85% and the molecular weight of this protein is around 95-135 kDa verified by SEC-MALS.

MM9-M52H1-MALS-HPLC
MMP-9 MALS images

The purity of Mouse MMP-9 (20-471), His Tag (Cat. No. MM9-M52H1) is more than 90% and the molecular weight of this protein is around 53-73 kDa verified by SEC-MALS.

Synonym Name

MMP9,CLG4B,GELB,MANDP2,Gelatinase B

Background

Matrix metallopeptidase 9 (MMP-9) is also known as 92 kDa type IV collagenase, 92 kDa gelatinase or gelatinase B (GELB), CLG4B, is secreted from neutrophils, macrophages, and a number of transformed cells, and is the most complex family member in terms of domain structure and regulation of its activity. . Structurally, MMP9 maybe be divided into five distinct domains: a prodomain which is cleaved upon activation, a gelatinbinding domain consisting of three contiguous fibronectin type II units, a catalytic domain containing the zinc binding site, a prolinerich linker region, and a carboxyl terminal hemopexinlike domain. This enzyme degrades various substrates including gelatin, collagen types IV and V, and elastin. MMP9 is involved in a variety of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, and be regarded as a potential therapeutic target.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Andecaliximab GS-5745 Phase 3 Clinical Cystic Fibrosis; Stomach Neoplasms; Esophageal Neoplasms; Arthritis, Rheumatoid; Pancreatic Neoplasms; Breast Neoplasms; Colitis, Ulcerative; Colorectal Neoplasms; Pulmonary Disease, Chronic Obstructive; Crohn Disease; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
AQU-005 AQU-005; NMAQU-005; NM-AQU-005 Phase 1 Clinical Aquilus Pharmaceuticals Neuralgia Details
CALY-001 CALY-001 Clinical Calypso Biotech Bv Inflammatory Bowel Diseases; Crohn Disease Details
Andecaliximab GS-5745 Phase 3 Clinical Cystic Fibrosis; Stomach Neoplasms; Esophageal Neoplasms; Arthritis, Rheumatoid; Pancreatic Neoplasms; Breast Neoplasms; Colitis, Ulcerative; Colorectal Neoplasms; Pulmonary Disease, Chronic Obstructive; Crohn Disease; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
AQU-005 AQU-005; NMAQU-005; NM-AQU-005 Phase 1 Clinical Aquilus Pharmaceuticals Neuralgia Details
CALY-001 CALY-001 Clinical Calypso Biotech Bv Inflammatory Bowel Diseases; Crohn Disease Details

This web search service is supported by Google Inc.

totop

Laisser un message